Recurrence Rate of Colorectal Adenomas Reduced With Endoscopic Submucosal Dissection
(MedPage Today) -- Endoscopic submucosal dissection (ESD) of large colorectal adenomas resulted in a lower recurrence rate compared with endoscopic mucosal resection (EMR), but the more technically complex ESD had a higher rate of adverse events... (Source: MedPage Today Surgery)
Source: MedPage Today Surgery - December 11, 2023 Category: Surgery Source Type: news
New Robotic-Assisted Surgery Offers Inspiring Hope for Rwanda
An artist’s impression of the completed Centre of Excellence in Kigali. The center supported by IRCAD is expected to assist with the training of surgeons throughout the continent with minimally invasive surgery training. Credit: SuppliedBy Aimable TwahirwaKIGALI, Nov 13 2023 (IPS) In a newly established Centre of Excellence located in Masaka, a suburb of the Rwandan capital city, Kigali, an expanded lab, complete with innovative facilities and specialized instruments, is now giving surgeons a conducive environment to simulate how to perform minimally invasive surgeries.
French-based Institute for Research into Cancer ...
Source: IPS Inter Press Service - Health - November 13, 2023 Category: International Medicine & Public Health Authors: Aimable Twahirwa Tags: Africa Featured Health Innovation TerraViva United Nations IPS UN Bureau IPS UN Bureau Report Rwanda Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche enters into a definitive agreement to acquire Telavant including rights to novel TL1A directed antibody (RVT-3101) for the treatment of inflammatory bowel disease from Roivant
Roche will gain the rights to develop, manufacture and commercialise RVT-3101 in the US and Japan for the treatment of inflammatory bowel disease and potentially multiple other diseasesRVT-3101 is a Phase 3-ready antibody with first-in-class and best-in-disease potential, a novel mode of action and strong Phase 2b data in ulcerative colitisRoche will also obtain an option to enter into a global collaboration with Pfizer on a next-generation p40/TL1A directed bispecific antibody, currently in Phase 1Under the terms of the agreement, Roche will pay a purchase price of US$ 7.1 billion upfront and a near-term milestone payment...
Source: Roche Investor Update - October 23, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche enters into a definitive agreement to acquire Telavant including rights to novel TL1A directed antibody (RVT-3101) for the treatment of inflammatory bowel disease from Roivant
Roche will gain the rights to develop, manufacture and commercialise RVT-3101 in the US and Japan for the treatment of inflammatory bowel disease and potentially multiple other diseasesRVT-3101 is a Phase 3-ready antibody with first-in-class and best-in-disease potential, a novel mode of action and strong Phase 2b data in ulcerative colitisRoche will also obtain an option to enter into a global collaboration with Pfizer on a next-generation p40/TL1A directed bispecific antibody, currently in Phase 1Under the terms of the agreement, Roche will pay a purchase price of US$ 7.1 billion upfront and a near-term milestone payment...
Source: Roche Media News - October 23, 2023 Category: Pharmaceuticals Source Type: news
First Phase 3 TREMFYA ® (guselkumab) Data in Inflammatory Bowel Disease Show Positive Induction Results Among Patients with Moderately to Severely Active Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, May 9, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new efficacy and safety data from the Phase 3 QUASAR Induction Study evaluating the investigational use of TREMFYA® (guselkumab) in adults with moderately to severely active ulcerative colitis (UC)a who had an inadequate response or intolerance to conventionalb and/or advanced therapies.1,c The data show statistically significant and clinically meaningful improvements across symptomatic and histo-endoscopic outcome measures.1 Safety data were also consistent with the known safety profile of TREMFYA in ...
Source: Johnson and Johnson - May 9, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
New STELARA ® (ustekinumab) Long-Term Data Support its Established Safety Profile in Inflammatory Bowel Disease and Durable Efficacy in Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, March 4, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final pooled long-term safety results for STELARA® (ustekinumab) through five years in adults with moderately to severely active Crohn’s disease (CD) and four years in adults with moderately to severely active ulcerative colitis (UC), as well as final four-year clinical and endoscopic outcomes from the UNIFI long-term extension (LTE) study evaluating the efficacy of STELARA for the treatment of adults with moderately to severely active UC.1,2 These data are a part of Janssen’s 22 oral and poster ...
Source: Johnson and Johnson - March 4, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
TREMFYA ® (guselkumab) Demonstrates a Differentiated Binding Mechanism from Risankizumab in In Vitro Studies
SPRING HOUSE, PENNSYLVANIA, March 3, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced additional results from in vitro MODIF-Y studies, which continue to support a hypothesis that not all IL-23 inhibitors are the same by demonstrating a differentiated binding mechanism for TREMFYA® (guselkumab) from risankizumab. Findings show that guselkumab is able to dose-dependently bind to CD64+a myeloid cells,1 the predominant source of IL-23-driven inflammation in the gut.2,b Data comprise one of Janssen’s 22 oral and poster presentations at the 18th Congress of the European Crohn’s and Col...
Source: Johnson and Johnson - March 3, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Duodenoscopes With Disposable Caps Led to Less Microbial Contamination
(MedPage Today) -- Use of duodenoscopes with disposable elevator caps during endoscopic retrograde cholangiopancreatography (ERCP) led to lower rates of contamination following high-level disinfection compared with standard scope designs, and did... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - January 24, 2023 Category: Gastroenterology Source Type: news
New TREMFYA ® (guselkumab) Data Show an Overall Clinical Response Rate of Approximately 80 Percent in a Phase 2b Induction Study of Adults with Moderately to Severely Active Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2b QUASAR Induction Study 1 in adults with moderately to severely active ulcerative colitis (UC) with inadequate responses to previous treatments. The data presented at the 2022 American College of Gastroenterology (ACG) Annual Scientific Meeting show an overall clinical response rate of approximately 80 percent in patients who were randomized to TREMFYA® (guselkumab).Clinical responsea at weeks 12 or 24 of the study was ultimately achieved by 80.2 percent of patients who w...
Source: Johnson and Johnson - October 24, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Transnasal Endoscopy Tested in Primary Care for Esophageal Screen Transnasal Endoscopy Tested in Primary Care for Esophageal Screen
With a lower price tag and fewer complications than sedated endoscopy, experts said the transnasal approach could help primary care physicians catch potential GI cancers early.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 17, 2022 Category: Cancer & Oncology Tags: Gastroenterology News Source Type: news
Results of Novel Clinical Study of Guselkumab and Golimumab Combination Therapy Show Adults with Moderately to Severely Active Ulcerative Colitis Maintained Higher Rates of Clinical, Histologic, and Endoscopic Remission at Week 38
SPRING HOUSE, PENNSYLVANIA, October 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from an ongoing analysis of a Phase 2a clinical trial showing adults with moderately to severely active ulcerative colitis (UC) who received 12 weeks of combination induction therapy with guselkumab and golimumab, followed by a transition to guselkumab alone for maintenance, achieved a clinical remission ratea (based on the modified Mayo score [mMayo])b at week 38 of 47.9 percent, a higher rate than induction and maintenance treatment with either guselkumab alone (31.0 percent) or golimumab al...
Source: Johnson and Johnson - October 10, 2022 Category: Pharmaceuticals Source Type: news
Complete Endoscopic Healing in IBD Linked to Lower Relapse Risk
(MedPage Today) -- Patients with inflammatory bowel disease (IBD) have a high risk of relapse after stopping tumor necrosis factor (TNF) inhibitors, but those who achieved complete endoscopic healing had a far lower risk, according to a prospective... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - September 2, 2022 Category: Gastroenterology Source Type: news
How to Remove Foreign Bodies?
Discussion
Living in the world makes the human body susceptible to foreign bodies. Orifices are particularly inviting for children to explore and see how it feels if the opening is touched by their hands or an object. Small objects are easily inserted or even just retained (such as toilet tissue in the genital area, or tissue in the nose). The mouth is particularly inviting to explore objects with as oral sensations are paramount to survival even at birth. Food can be considered a foreign body and often acts like one when stuck in the respiratory or gastrointestinal tract but is necessary to sustain life.
When someone says...
Source: PediatricEducation.org - July 4, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA ® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
SPRING HOUSE, PENNSYLVANIA, May 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2 GALAXI 1 clinical trial of TREMFYA® (guselkumab) in adult patients with moderately to severely active Crohn’s disease (CD), and from three separate long-term pooled analyses of adult patients with ulcerative colitis (UC) and CD treated with STELARA® (ustekinumab).1,2,3,4 These data are being presented as oral and poster presentations and are among 29 Janssen abstracts presented during the Digestive Disease Week® (DDW) meeting taking place in person and virtually in San Di...
Source: Johnson and Johnson - May 24, 2022 Category: Pharmaceuticals Source Type: news
Noninvasive Esophageal Cancer Screening May Reach More Patients Noninvasive Esophageal Cancer Screening May Reach More Patients
Noninvasive approaches have lower sensitivity and specificity than endoscopic screening, but greater access could make them cost effective.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - May 10, 2022 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
